Grant of Share Options & PDMR Dealings

Genincode

26/03/2025 07:45

RNS Number : 2718C

GENinCode PLC

26 March 2025

 

 

 

26 March 2025

 

 

GENinCode Plc

("GENinCode" or the "Company")

 

Grant of Share Options & PDMR Dealings

 

 

GENinCode Plc (AIM: GENI), the genetics company focused on the prevention of cardiovascular disease and ovarian cancer, announces that on 21 March 2025 the Company approved the grant of options over an aggregate of 14,028,305 new ordinary shares of 1 pence each in the Company ('Ordinary Shares') under the 2021 Share Option Plan ('2021 Share Option Plan') to certain directors and employees of the Company (the "New Options"), representing 4.89% per cent. of the Company's existing issued share capital.

 

Terms of the New Options

 

The Company adopted the 2021 Share Option Plan to enable it to retain and incentivise staff and to reward them for the achievement of its longer-term objectives. 14,028,305 New Options will be issued at an exercise price of 3.7 pence per share which are exercisable on the second anniversary of the date of grant. There are no other vesting criteria for the New Options which have a 10-year term.

 

Details of resultant holdings

 

Following the New Options grant and the Option Surrender, details of Options held by Directors, PDMRs and other employees of the Company, are as follows:

 

Director's name
Position
Number of New Options granted at 3.7 pence
Aggregate number of options post grant
Current total beneficial holding of Ordinary Shares
Current holding as a % of Issued share capital
Matthew Walls
CEO
2,431,082
5,254,832
12,235,473
4.26%
Paul Foulger
CFO
2,216,062
4,790,062
1,273,587
0.44%
Jordi Puig
COO
1,462,524
3,161,274
14,737,636
5.14%
William Rhodes
Non-Executive Chair
554,016
1,197,516
-
0.0%
Huon Gray
Non-Executive Director
387,423
837,423
905,405
0.32%
Felix Frueh
Non-Executive Director
387,423
837,423
100,000
0.03%
Sergio Olivero
Non-Executive Director
172,188
172,188
7,417,243
2.59%
Other Employees
6,417,587
16,912,905
N/A
N/A
Total:
12,640,526
32,991,435
36,669,344
12.78%

 

 

Following the grant of the New Options, there are Options over a total of 32,915,560 Ordinary Shares in the Company as at the date of this announcement, representing approximately 11.47% of the Company's existing issued share capital. 

 

For more information visit www.genincode.com

Enquiries:

 

GENinCode Plc
www.genincode.comor via Walbrook PR
Matthew Walls, CEO
Paul Foulger, CFO
Cavendish Capital Markets Limited
Tel: +44 (0)20 7397 8900
Giles Balleny /Dan Hodkinson (Corporate Finance)
Dale Bellis / Michael Johnson (Sales)
Nigel Birks (Life Sciences Specialist Sales)
Ondraya Swanson (Corporate Broking)
Walbrook PR Limited
Anna Dunphy / Paul McManus / Louis Ashe-Jepson
Tel: 020 7933 8780 or genincode@walbrookpr.com


 

About GENinCode:

GENinCode Plc is a UK based company specialising in genetic risk assessment of cardiovascular disease. Cardiovascular disease is the leading cause of death and disability worldwide.

 

GENinCode operates business units in the UK, Europe through GENinCode S.L.U, and in the United States through GENinCode U.S. Inc.

 

GENinCode predictive technology provides patients and physicians with globally leading preventative care and treatment strategies. GENinCode CE marked invitro-diagnostic molecular tests combine clinical algorithms and bioinformatics to provide advanced patient risk assessment to predict cardiovascular disease.

 

 

The notification set out below is provided in accordance with the requirements of MAR.

 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1
Details of the person discharging managerial responsibilities/person closely associated
a.
Name
1. Matthew Walls
2. Paul Foulger
3. Jordi Puig
4. William Rhodes
5. Huon Gray
6. Felix Frueh
7. Sergio Olivero
2
Reason for notification
a.
Position/Status
1. Chief Executive Officer
2. Chief Financial Officer
3. Chief Operating Officer
4. Non-Executive Chair
5. Non-Executive Director
6. Non-Executive Director
7. Non-Executive Director
b.
Initial notification/
Amendment
Initial Notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.
Name
GENinCode Plc
b.
LEI
213800UX6TE7K65O2892
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.
Description of the financial instrument, type of instrument

Identification Code
Options over Ordinary Shares of 1p each
N/A
b.
Nature of the transaction
Grant of options under the 2021 Share Option Plan with time vesting conditions attached
c.
Price(s) and volume(s)
Exercise Price(s)
Volume(s)
1.
3.7pence
2,431,082
2.
3.7pence
2,216,062
3.
3.7pence
1,462,524
4.
3.7pence
554,016
5.
3.7pence
387,423
6.
3.7pence
387,423
7.
3.7 pence
172,188
d.
Aggregated information
- Aggregated Volume
- Price
See above
e.
Date of the transaction
21 March 2025
f.
Place of the transaction
Outside a trading venue


 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 
  END

 

 
DSHUNOBRVSUOURR